MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
2.300
+0.170
+7.98%
After Hours: 2.299 -0.001 -0.03% 19:59 12/01 EST
OPEN
2.130
PREV CLOSE
2.130
HIGH
2.300
LOW
2.020
VOLUME
3.04M
TURNOVER
0
52 WEEK HIGH
10.99
52 WEEK LOW
1.430
MARKET CAP
256.14M
P/E (TTM)
-0.8822
1D
5D
1M
3M
1Y
5Y
The most crowded pharma longs and shorts, according to UBS
The most crowded pharma longs and shorts, according to ubs. Crowding is a sentiment metric that measures popularity in positioning. United therapeutics corp. Is the most crowded longs in the u.s. Pharmaceutical sector. Ubs measures crowding based on prime brokerage data and 13f filings.
Seeking Alpha · 1d ago
Buy Rating on Coherus Biosciences Anchored by Competitive Pricing and Market Strategy for Loqtorzi
TipRanks · 3d ago
Coherus cancer drug undercuts Merck's Keytruda
Healthcare coherus cancer drug undercuts merck's keytruda. Baird estimates loqtorzi will generate peak annual sales of around $150m in the u.s. For nasopharyngeal carcinoma. Coheru biosciences reports list pricing of its newly-approved cancer drug, $8892.03.
Seeking Alpha · 4d ago
What 6 Analyst Ratings Have To Say About Coherus BioSciences
Cherus biosciences has 6 analysts rating the stock. These 6 analysts have an average price target of $13.83 versus the current price of $1.995. The greater the number of bullish ratings, the more positive analysts are on the company.
Benzinga · 4d ago
Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Benzinga · 4d ago
Coherus And Junshi Biosciences Announce Publication Of Final Overall Survival Results Of JUPITER-02, A Phase 3 Trial Evaluating LOQTORZI As Treatment For Nasopharyngeal Carcinoma, In The Journal Of The American Medical Association
Final overall survival analysis of the jupiter-02 trial shows first-line treatment with loqtorzi plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone. Loq torzi is the first and only fda-approved treatment for npc in all lines of therapy. Coherus plans to launch the drug in the u.s. In january 2024.
Benzinga · 4d ago
Coherus Bioscien: Current report
Press release · 5d ago
Weekly Report: what happened at CHRS last week (1120-1124)?
Weekly Report · 5d ago
More
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. The Company markets UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States (the U.S). It also sells CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, in the U.S. The Company also focused on developing Humira, a biosimilar YUSIMRY (adalimumab-aqvh) in the U.S.

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.